Perioperative Hyperglycaemia in Primary Total Hip and Knee Replacement
HyTe-1
Determinants of Perioperative Hyperglycaemia in Primary Hip and Knee Replacement
1 other identifier
observational
193
1 country
1
Brief Summary
The purpose of this study is to analyze how common stress hyperglycaemia (abnormally high blood glucose) is in primary hip and knee replacement surgeries and which factors predispose to hyperglycaemia.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Dec 2009
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 27, 2009
CompletedFirst Posted
Study publicly available on registry
November 30, 2009
CompletedStudy Start
First participant enrolled
December 1, 2009
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2011
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2012
CompletedAugust 11, 2015
August 1, 2015
1.6 years
November 27, 2009
August 9, 2015
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Occurrence (and severity) of hyperglycemia following primary hip or knee replacement
Follow-up covers postoperative hospital stay at the operating hospital, that lasts typically 2-5 days.
3 days (average)
Secondary Outcomes (2)
Incidence of surgical-site infections
1 year
Prevalence of glucose metabolism disorders and metabolic syndrome
Baseline
Study Arms (1)
Hip and knee replacements recipients
Osteoarthritis patients undergoing elective primary hip and knee replacement and being followed-up in this study.
Eligibility Criteria
tertiary care clinic
You may qualify if:
- Diagnosis of osteoarthritis
- Scheduled for primary hip or knee replacement
You may not qualify if:
- Arthritis other than osteoarthritis
- Medication affecting glucose metabolism (excl. antidiabetic agents)
- Not undergoing hip or knee replacement
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Coxa, Hospital for Joint Replacementlead
- Tampere Universitycollaborator
Study Sites (1)
Coxa, Hospital for Joint Replacement
Tampere, 33580, Finland
Related Publications (1)
Jamsen E, Nevalainen PI, Eskelinen A, Kalliovalkama J, Moilanen T. Risk factors for perioperative hyperglycemia in primary hip and knee replacements. Acta Orthop. 2015 Apr;86(2):175-82. doi: 10.3109/17453674.2014.987064. Epub 2014 Nov 18.
PMID: 25409255RESULT
Biospecimen
plasma sample (one per patient, collected before surgery)
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Teemu Moilanen, MD, PhD
Coxa, Hospital for Joint Replacement
- PRINCIPAL INVESTIGATOR
Esa Jämsen, MD, PhD
Coxa, Hospital for Joint Replacement
- PRINCIPAL INVESTIGATOR
Pasi Nevalainen, MD, PhD
Tampere University Hospital
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- MD, PhD, Researcher
Study Record Dates
First Submitted
November 27, 2009
First Posted
November 30, 2009
Study Start
December 1, 2009
Primary Completion
July 1, 2011
Study Completion
September 1, 2012
Last Updated
August 11, 2015
Record last verified: 2015-08